CSTL · Castle Biosciences, Inc. · Stock research

Current Thesis

The narrative leg is unchanged in substance and changed in price: a gastroenterology assay (TissueCypher, for Barrett's esophagus) compounding fast enough to overwhelm a dermatology franchise that has stopped growing. What is new is the tape. The shares closed $34.20 on 2026-08-21 against $29.62 on 2026-08-14, and the only company releases in that window were a 2026-08-17 approval for a dual listing on Nasdaq Texas (primary listing retained on the Nasdaq Global Market) and a 2026-08-20 notice of two September investor conferences. Neither carries revenue, guidance or volume content. The advance since mid-August therefore rests on the 2026-07-30 beat-and-raise being re-priced rather than on any datapoint filed since. Distance to the 52-week high of $43.04 narrowed from −31.2% at the 2026-08-14 close to −20.5% at the 2026-08-21 close.

Bullish and bearish views on Castle Biosciences, Inc.

The model's bull view on Castle Biosciences, Inc. (CSTL), in brief: The raise was printed, not briefed. On 2026-07-30 Castle reported Q2 2026 revenue of $103.5M versus $86.2M in Q2 2025 (+20.1%) and adjusted EPS of $(0.07) against a $(0.41) consensus estimate, and lifted FY2026 revenue guidance to $365–375M from $345–355M against a $352.291M… The bear view: The legacy base is flat to shrinking. Q2 2026 report counts: DecisionDx-Melanoma 10,280 (+3% YoY), DecisionDx-SCC 4,011 (−16%), MyPath Melanoma 1,061 (−9%), DecisionDx-UM 482 (+3%). At Canaccord Genuity's growth conference on 2026-08-12 management described continued mid-to-high… Both cases follow in full.

Bull Case

• The raise was printed, not briefed. On 2026-07-30 Castle reported Q2 2026 revenue of $103.5M versus $86.2M in Q2 2025 (+20.1%) and adjusted EPS of $(0.07) against a $(0.41) consensus estimate, and lifted FY2026 revenue guidance to $365–375M from $345–355M against a $352.291M consensus figure per Benzinga's tally.
• The growth line is countable. TissueCypher delivered 14,988 test reports in Q2 2026 versus 9,170 a year earlier (+64%). Management guided full-year 2026 TissueCypher volume growth to 50–52%.
• Operating leverage arrived alongside it. Adjusted EBITDA of $12.4M in Q2 2026 versus $10.4M in Q2 2025, on GAAP gross margin of 75% (76% adjusted). Management guided to positive Adjusted EBITDA for Q3, Q4 and the full year.
• No near-term financing question. Cash and marketable securities of $266.8M at 2026-06-30, against a Q2 GAAP net loss of $2.1M. No offering, ATM activation or convertible has been announced since the 07-30 print.
• Sell-side re-marked after the print. BTIG maintained Buy and raised its target to $44 on 2026-08-03; Roth/MKM had initiated at Buy with a $40 target in late June 2026 (report dated 2026-06-26). BTIG's $44 sits above the 2026-08-21 close of $34.20.
• Pipeline milestones have dates. AdvanceAD-Tx received New York State Department of Health approval on 2026-07-14; the DETECT-AD study enrolled its first patient in June 2026.

Bear Case

• The legacy base is flat to shrinking. Q2 2026 report counts: DecisionDx-Melanoma 10,280 (+3% YoY), DecisionDx-SCC 4,011 (−16%), MyPath Melanoma 1,061 (−9%), DecisionDx-UM 482 (+3%). At Canaccord Genuity's growth conference on 2026-08-12 management described continued mid-to-high single-digit volume growth for DecisionDx-Melanoma — better than the Q2 print, still not an engine.
• DecisionDx-SCC remains outside Medicare coverage following a 2025 coverage change; the sixteen-percent decline in SCC reports is the visible cost. No CMS/MolDX date has been confirmed by the company.
• Concentration migrated rather than resolved. One gastroenterology assay now carries the re-acceleration, and its adoption curve has never been tested through a reimbursement dispute of the kind SCC ran into.
• Profitability is adjusted. A $2.1M GAAP net loss beside $12.4M of Adjusted EBITDA in Q2 2026 is the gap a reader has to hold.
• Part of the raise was attributed to average selling price, which is set by payer behaviour and can reverse with volumes unchanged.
• The last leg had no fundamental content behind it. Roughly a third of the gap to the $43.04 high closed between 2026-08-14 and 2026-08-21 on a dual-listing approval and a conference calendar.

Setup & Price Structure

• Reference close 2026-08-21: $34.20. RSI(14) 65.0. Three-month price change +69.7%. The 52-week high of $43.04 sits 20.5% above the last close.
• The post-print shelf that framed the prior four weeks is the $29–30 area: the CCO's Form 4 executed at $29.21 on 2026-08-03 and the 2026-08-14 close was $29.62. The week ending 2026-08-21 cleared it.
• The narrative is maturing. Dating the call: the beat-and-raise is 2026-07-30, BTIG's re-mark 2026-08-03, the last management appearance 2026-08-12. The releases since — 2026-08-17 dual listing, 2026-08-20 conference schedule — carry no financial content, and the largest advance of the leg came in that same stretch. Widely reported, still working, information flow thinning.
• there is no earnings date inside the next 30 days; the two dated events in that window are conference appearances, one of them one-on-one meetings with no webcast; RSI(14) reads 65.0 at 2026-08-21 versus 69.5 at 2026-08-14, so the momentum reading did not extend with the price.

Catalyst Calendar (next 30 days)

• 2026-09-10 — Lake Street Best Ideas Growth (BIG10) Conference. One-on-one investor meetings only, requested through Lake Street Capital Markets; no webcast, so no public disclosure is scheduled.
• 2026-09-15, 10:50 a.m. ET — Baird 2026 Global Healthcare Conference, company overview presentation with live audio webcast (announced 2026-08-20). First public management appearance since 2026-08-12 and the only scheduled opportunity inside 30 days for the FY26 $365–375M range or the 50–52% TissueCypher volume guide to be addressed.
• ~2026-11-03 (est.) — Q3 2026 results. Outside the 30-day window; historically the first week of November.
• ~2026-Q4, no date confirmed — CMS/MolDX update on DecisionDx-SCC Medicare coverage. Not on a company-controlled timetable.

What Would Change Our Mind

The structure at risk is the $29–30 shelf the week ending 2026-08-21 cleared; losing it back would put price inside the range that held from the print through 2026-08-14 and undo the August advance. The gradeable version: a weekly close below $29. Beyond price, three observables would break the frame. First, the 2026-09-15 Baird appearance passing without a reaffirmation of the $365–375M FY26 revenue range or the 50–52% TissueCypher volume trajectory — the leg has already priced both as safe. Second, a Q3 print (est. ~2026-11-03) with TissueCypher report counts implying full-year growth under 50%, or an FY26 guide walked back below $365M. Third, an S-3 takedown, ATM activation or convertible announcement into strength, which would re-open the financing question the $266.8M cash position currently closes. A CMS/MolDX decision declining SCC reinstatement would not break the thesis — current guidance does not assume it — but would confirm the single-product concentration.

Correlation Notes

• CSTL trades in the small- and mid-cap molecular diagnostics complex, where the dominant shared factor is reimbursement policy: CMS/MolDX coverage decisions and gene-expression-profile payment rates move the group together, independent of company results. Peers in that news cycle include Exact Sciences, Natera, Veracyte and Myriad Genetics.
• The name has no AI-capex or semiconductor exposure; drawdowns driven by the AI hardware complex are not a mechanical read-through here. The relevant macro sensitivities are small-cap risk appetite and the biotech/diagnostics tape.
• The 2026-08-17 Nasdaq Texas approval is a dual listing with the primary listing retained on the Nasdaq Global Market. It adds a venue; it does not change index membership, share count or float.